This episode is brought to you by:

Tegus. Tegus, the modern research platform for leading investors. Stretch your research budget with flexible expert calls you can trust. At a fraction of the cost of traditional expert networks, Tegus customers pay only what an expert charges – with zero markups and no confusing call credits – netting an average 70% savings. Don’t want to conduct a full hour call? Tegus offers the ability to schedule 30-minutes, an offer you won’t find anywhere else. And they don’t stop there. With white-glove custom sourcing for every project and robust compliance measures, including a dedicated 50+ analyst team that vets every call transcript, Tegus ensures your privacy and protection. As the industry innovator for qualitative insights, Tegus helps you find the right experts you need at a quality and speed that can’t be matched. For a limited time, as a listener, you can trial Tegus for free by visiting tegus.co/patrick.

Shownotes

(00:03:49) - (First question) - Ways the immune system protects us and fails us

(00:06:00) - Current patient treatments and evolving solutions to existing problems

(00:07:52) - The key difference between how the biotech community is addressing big diseases versus autoimmune disorders

(00:09:55) - What sparked Julia’s interest in ArgenX

(00:14:01) - Explanation how we use animal antibodies to help research progression

(00:15:25) - The foundations of the business

(00:17:57) - The evolution of the business and its commercial success thus far

(00:20:22) - Transitioning from lab antibodies to a commercial product ready for consumers

(00:23:42) - The infrastructure needed to maintain and grow ArgenX

(00:26:43) - Indicators of commercial success

(00:29:27) - The basic revenue model for this business type

(00:30:49) - Go to market strategies for developed drugs

(00:34:39) - Pricing and patient protection of these newly developed drugs

(00:37:46) - Cures versus creating treatments with recurring revenue streams

(00:39:38) - The importance of the current team composition

(00:41:44) - Julia’s perspective on what they are willing to invest to grow the company

(00:43:49) - Normalized profitability for biotech companies such as this

(00:45:59) - Potential risks to the current business model

(00:47:30) - Educating yourself on the science behind the business for better investment knowledge

(00:49:22) - Lessons learned from studying ArgenX